Fortrea Holdings/$FTRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Fortrea Holdings
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
- Ticker
- $FTRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14,000
- Headquarters
- Durham, United States
- Website
- www.fortrea.com
Fortrea Holdings Metrics
BasicAdvanced
$1.9B
-
-$0.92
2.01
-
Price and volume
Market cap
$1.9B
Beta
2.01
52-week high
$21.39
52-week low
$8.31
Average daily volume
1.4M
Financial strength
Current ratio
0.958
Quick ratio
0.854
Long term debt to equity
2.082
Total debt to equity
2.132
Interest coverage (TTM)
0.31%
Profitability
EBITDA (TTM)
98.3
Gross margin (TTM)
19.30%
Net profit margin (TTM)
-3.18%
Operating margin (TTM)
0.97%
Effective tax rate (TTM)
-9.51%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
0.58%
Return on equity (TTM)
-15.30%
Valuation
Price to revenue (TTM)
0.693
Price to book
3.62
Price to tangible book (TTM)
-1.87
Price to free cash flow (TTM)
9.467
Free cash flow yield (TTM)
10.56%
Free cash flow per share (TTM)
2.105
Growth
Revenue change (TTM)
-2.09%
Earnings per share change (TTM)
-91.98%
3-year revenue growth (CAGR)
-3.11%
3-year earnings per share growth (CAGR)
-15.92%
What the Analysts think about Fortrea Holdings
Analyst ratings (Buy, Hold, Sell) for Fortrea Holdings stock.
Analyst projections of the future price of Fortrea Holdings stock.
Bulls say / Bears say
Fortrea raised its full-year 2026 guidance to revenues of $2,620 million–$2,690 million and adjusted EBITDA of $205 million–$220 million, reflecting management’s confidence in demand growth this year. (Fortrea Q2 2026 Press Release)
The company achieved a book-to-bill ratio of 1.06x for Q2 2026 and 1.12x on a trailing 12-month basis, marking four consecutive quarters above 1.0 and indicating robust contract demand. (Fortrea Q2 2026 Press Release)
Adjusted EBITDA grew to $58.7 million in Q2 2026 from $54.9 million in Q2 2025, underscoring improving operational leverage year-over-year. (Fortrea Q2 2026 Press Release)
Revenues fell 4.5% year-over-year to $678.2 million in Q2 2026 from $710.3 million in Q2 2025, signaling a slowdown in client spend. (Fortrea Q2 2026 Press Release; Fortrea Q2 2025 Results)
The company reported a GAAP net loss of $13.2 million in Q2 2026, remaining unprofitable at the operating level. (Fortrea Q2 2026 Press Release)
Free cash flow was only $19.9 million in the quarter (approximately 2.9% of revenue), which may limit reinvestment capacity. (Fortrea Q2 2026 Press Release)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Fortrea Holdings Financial Performance
Revenues and expenses
Fortrea Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
Fortrea Holdings News
AllArticlesVideos
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Benzinga3 weeks ago
Fortrea Q2 Earnings Call Highlights
MarketBeat2 months ago
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm
Business Wire2 months ago
Funds containing Fortrea Holdings
AllUSDEURGBP
Fund name | Fund size | $FTRE weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.20% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.20% |
iShares Healthcare Innovation£DRDR | £1B | 0.20% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.